Abstract

Liquid biopsy is a promising strategy for detecting and monitoring neoplastic diseases, with circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) being the most common objects of investigation. Most laboratories are focusing on these biomarkers separately and simultaneous detection has not yet been attempted in high grade serous tubo-ovarian carcinoma (HGSOC). This dataset comprises raw data obtained in the study in which we assess whether tandem CTC/ctDNA approach increases HGSOC detection efficiency. We developed specific liquid biopsy assays, all based on nucleic acid analyses. For CTC detection, we tested gene expression assays and TP53 next-generation sequencing (NGS), whereas the latter was also applied for ctDNA detection. The assays were then verified on two HGSOC cohorts and respective controls, demonstrating the complementary value of simultaneous CTC and cfDNA analysis in HGSOC. Specifically, this dataset contains (i) raw data obtained from all quantitative Real-Time PCR analyses, (ii) Sanger sequencing of patient germ-line tissue to confirm tumor-specific mutations, and (iii) microscopic images of the Parsortix-enriched ovarian cancer cells spiked in the healthy donor blood sample.